Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Mar;61(3):460–464. doi: 10.1038/bjc.1990.101

Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

P O Mulder 1, E G de Vries 1, D R Uges 1, A H Scaf 1, D T Sleijfer 1, N H Mulder 1
PMCID: PMC1971298  PMID: 2183874

Abstract

Pharmacokinetics of the cisplatin analogue carboplatin were studied in patients with disseminated ovarian and testicular cancer. Carboplatin 750 mg m-2 divided over three consecutive days was given as part of an ablative combination regimen followed by autologous bone marrow transplantation. Platinum (Pt) in plasma, plasma ultrafiltrate and urine was determined up to 96 h after the last drug dose by atomic absorption spectrometry. Carboplatin was measured by high performance liquid chromatography. The curves of ultrafiltrated Pt and carboplatin decayed in a bio-exponential way with t1/2 alpha of respectively 65 and 70 min and t1/2 beta of respectively 378 and 1014 min. The volumes of distribution (Vdss) were 18 and 25 l m-2, respectively, and total body clearances (ClTB) 79 and 65 ml min-1 m-2. Both curves overlapped when corrected for the Pt content of carboplatin. A diversion with the three-exponential curve of total Pt occurred between 3 and 6 h. After 10 h approximately 30% of the plasma Pt was protein bound. Total Pt had a larger Vdss (117 l m-2) and a lower total body clearance (14 ml min-1 m-2) than free Pt and carboplatin. Fifty-three per cent of the i.v. administered carboplatin was excreted in the urine in the first 6 h. Plasma ultrafiltrated Pt and carboplatin decreased to undetectable levels within 48 h, but total Pt was detectable until 96 h after the last carboplatin dose. However, this Pt is already bound to protein and unlikely to be cytotoxic to reinfused haemopoietic stem cells, so bone marrow reinfusion can be safely performed at 48 h after repeated dosing of carboplatin on three consecutive days.

Full text

PDF
460

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boxenbaum H. G., Riegelman S., Elashoff R. M. Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm. 1974 Apr;2(2):123–148. doi: 10.1007/BF01061504. [DOI] [PubMed] [Google Scholar]
  2. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  3. Canetta R., Rozencweig M., Carter S. K. Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 (Suppl A):125–136. doi: 10.1016/0305-7372(85)90027-1. [DOI] [PubMed] [Google Scholar]
  4. Curt G. A., Grygiel J. J., Corden B. J., Ozols R. F., Weiss R. B., Tell D. T., Myers C. E., Collins J. M. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). Cancer Res. 1983 Sep;43(9):4470–4473. [PubMed] [Google Scholar]
  5. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  6. Elferink F., van der Vijgh W. J., Klein I., Vermorken J. B., Gall H. E., Pinedo H. M. Pharmacokinetics of carboplatin after i.v. administration. Cancer Treat Rep. 1987 Dec;71(12):1231–1237. [PubMed] [Google Scholar]
  7. Evans B. D., Raju K. S., Calvert A. H., Harland S. J., Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983 Nov;67(11):997–1000. [PubMed] [Google Scholar]
  8. Gore M. E., Calvert A. H., Smith L. E. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1391–1397. doi: 10.1016/0277-5379(87)90125-8. [DOI] [PubMed] [Google Scholar]
  9. Gormley P. E., Bull J. M., LeRoy A. F., Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther. 1979 Mar;25(3):351–357. doi: 10.1002/cpt1979253351. [DOI] [PubMed] [Google Scholar]
  10. Greenblatt D. J., Kock-Weser J. Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975 Oct 2;293(14):702–705. doi: 10.1056/NEJM197510022931406. [DOI] [PubMed] [Google Scholar]
  11. Harland S. J., Newell D. R., Siddik Z. H., Chadwick R., Calvert A. H., Harrap K. R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed] [Google Scholar]
  12. Hegedüs L., van der Vijgh W. J., Klein I., Kerpel-Fronius S., Pinedo H. M. Chemical reactivity of cisplatin bound to human plasma proteins. Cancer Chemother Pharmacol. 1987;20(3):211–212. doi: 10.1007/BF00570487. [DOI] [PubMed] [Google Scholar]
  13. Knox R. J., Friedlos F., Lydall D. A., Roberts J. J. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972–1979. [PubMed] [Google Scholar]
  14. Koeller J. M., Trump D. L., Tutsch K. D., Earhart R. H., Davis T. E., Tormey D. C. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer. 1986 Jan 15;57(2):222–225. doi: 10.1002/1097-0142(19860115)57:2<222::aid-cncr2820570206>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  15. LeRoy A. F., Wehling M. L., Sponseller H. L., Friauf W. S., Solomon R. E., Dedrick R. L., Litterst C. L., Gram T. E., Guarino A. M., Becker D. A. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 1977 Oct;18(2):184–191. doi: 10.1016/0006-2944(77)90089-8. [DOI] [PubMed] [Google Scholar]
  16. Leyvraz S., Ohnuma T., Lassus M., Holland J. F. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol. 1985 Oct;3(10):1385–1392. doi: 10.1200/JCO.1985.3.10.1385. [DOI] [PubMed] [Google Scholar]
  17. Loo J. C., Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970 Jan;59(1):53–55. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
  18. Micetich K. C., Barnes D., Erickson L. C. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Cancer Res. 1985 Sep;45(9):4043–4047. [PubMed] [Google Scholar]
  19. Mulder P. O., Sleijfer D. T., de Vries E. G., Uges D. R., Mulder N. H. Renal dysfunction following high-dose carboplatin treatment. J Cancer Res Clin Oncol. 1988;114(2):212–214. doi: 10.1007/BF00417840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Newell D. R., Siddik Z. H., Gumbrell L. A., Boxall F. E., Gore M. E., Smith I. E., Calvert A. H. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1399–1405. doi: 10.1016/0277-5379(87)90126-x. [DOI] [PubMed] [Google Scholar]
  21. Reece P. A., Bishop J. F., Olver I. N., Stafford I., Hillcoat B. L., Morstyn G. Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma. Cancer Chemother Pharmacol. 1987;19(4):326–330. doi: 10.1007/BF00261482. [DOI] [PubMed] [Google Scholar]
  22. Reece P. A., Stafford I., Russell J., Gill P. G. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol. 1986 Sep;4(9):1392–1398. doi: 10.1200/JCO.1986.4.9.1392. [DOI] [PubMed] [Google Scholar]
  23. Rozencweig M., Nicaise C., Beer M., Crespeigne N., Van Rijmenant M., Lenaz L., Kenis Y. Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol. 1983 Oct;1(10):621–626. doi: 10.1200/JCO.1983.1.10.621. [DOI] [PubMed] [Google Scholar]
  24. Scaf A. H. Pharmacokinetic analyses with RUGFIT: an interactive pharmacokinetic computer program. Biopharm Drug Dispos. 1988 Sep-Oct;9(5):415–446. doi: 10.1002/bod.2510090502. [DOI] [PubMed] [Google Scholar]
  25. Takahashi H., Sasaki Y., Saijo N., Sakurai M., Nakano H., Nakagawa K., Hoshi A., Jett J. R., Hong W. S. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin. Cancer Chemother Pharmacol. 1987;19(3):197–200. doi: 10.1007/BF00252972. [DOI] [PubMed] [Google Scholar]
  26. Trump D. L., Grem J. L., Tutsch K. D., Willson J. K., Simon K. J., Alberti D., Storer B., Tormey D. C. Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. J Clin Oncol. 1987 Aug;5(8):1281–1289. doi: 10.1200/JCO.1987.5.8.1281. [DOI] [PubMed] [Google Scholar]
  27. Van Echo D. A., Egorin M. J., Whitacre M. Y., Olman E. A., Aisner J. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep. 1984 Sep;68(9):1103–1114. [PubMed] [Google Scholar]
  28. Weiner M. W., Jacobs C. Mechanism of cisplatin nephrotoxicity. Fed Proc. 1983 Oct;42(13):2974–2978. [PubMed] [Google Scholar]
  29. van der Vijgh W. J., Klein I. Protein binding of five platinum compounds. Comparison of two ultrafiltration systems. Cancer Chemother Pharmacol. 1986;18(2):129–132. doi: 10.1007/BF00262281. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES